mathom/ct_dataset huggingface dataset:
Provide description for trial id: NCT04450264  
 New York City (NYC) is home to a large and diverse immigrant population. Many of these groups face significant barriers to preventive health care, including lack of insurance, poor health care access and language difficulties. Most African immigrant women are likely to live below the poverty line and have low health literacy, are less likely to have health insurance and visit a doctor, particularly for primary/preventive care. Without access to primary care, many preventive services, such as breast cancer screenings go unattended. The barriers and facilitators to breast cancer screening for other minority groups from underserved populations, such as African Americans and Latina women have been studied. Less is known about these for African immigrant women and how to most effectively engage their participation in regular screening. Data of over 2,000 African-born immigrants living in NYC show that 77% report not having health insurance; 75% do not have a primary care physician; and 57% have less than a high school education. As for cancer screening, when corrected for age, 44% have never had a mammogram. Through the study team's unique collaboration with the African Services Committee and the African Advisory Council of the Bronx, two non-governmental community-based service organizations, the study team is poised to have a significant impact on these immigrant women, who have emigrated from more than 20 countries in Africa. This is a population with great need for increased breast cancer knowledge, access to breast cancer screening, and basic medical care. The Health Belief Model (HBM) provides a framework for addressing cultural health barriers by positing that making a decision to engage in a health behavior is determined by weighing perceived threats versus benefits. The long term goal of the proposed project is to conduct a randomized clinical trial that tests the adapted intervention to increase breast cancer screening rates for African-born immigrants. In the short term, the study team plans to pursue the following specific aims: (1) Identify barriers and facilitators to breast cancer screening among African-born immigrants and (2) Culturally adapt and pilot test the Witness Project breast cancer education program for African-born women. Thus, the study team will culturally adapt an effective, innovative intervention to address this significant health disparity in African-born immigrant communities.
Trial Id: A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers Recruitment Status: Completed Trail description: In this study, the investigators will enroll women with palpable cancers to assess the accuracy of the Breast Cancer Locator (BCL) and the concomitant procedure as a vehicle to optimize and validate the approach in such surgical cases. This approach of adopting palpable cancer patients before initiating an evaluative trial of the BCL in non-palpable breast cancer cases ensures that the BCL does not substantially alter or modify the standard-of-care procedure. Inclusion Criteria: Age greater than or equal to 18 years
Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ
Patient desire to undergo breast surgery
Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted
The cancer enhances on breast MRI imaging. Exclusion Criteria: Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes
Severe claustrophobia
Contraindication to use of gadolinium-based intravenous contrast, including life-threatening allergy or compromised renal function (creatinine > 2.0)
History of median sternotomy
Pregnancy. Patient attestation that they are not pregnant will be acceptable as per standard policy for MRIs at DHMC.
Provide exclusion criteria for trial id: NCT02550210  
 Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes
Severe claustrophobia
Contraindication to use of gadolinium-based intravenous contrast, including life-threatening allergy or compromised renal function (creatinine > 2.0)
History of median sternotomy
Pregnancy. Patient attestation that they are not pregnant will be acceptable as per standard policy for MRIs at DHMC.
Provide description for trial id: NCT02550210  
 In this study, the investigators will enroll women with palpable cancers to assess the accuracy of the Breast Cancer Locator (BCL) and the concomitant procedure as a vehicle to optimize and validate the approach in such surgical cases. This approach of adopting palpable cancer patients before initiating an evaluative trial of the BCL in non-palpable breast cancer cases ensures that the BCL does not substantially alter or modify the standard-of-care procedure.
Trial Id: The HIFUB Study (HIFU in Breast Cancer) Recruitment Status: Unknown status Trail description: High Intensity Focused Ultrasound (HIFU) is a new method of treating solid tumours by thermally ablating them. It has been used in a number of different types of cancers but there is little information on its use in invasive breast cancer (IBC). The investigators aim to assess the efficacy and safety of HIFU in the treatment of IBC.

In this study, fifteen otherwise healthy women diagnosed with small, early stage IBC will be treated with HIFU prior to conventional surgical treatment. The effects of HIFU on the resected tumour will be analysed pathologically and correlated with radiological findings. Immune response and participant experience will also be evaluated Inclusion Criteria: Participant is willing and able to give informed consent for participation in the trial.
Female, aged 18 years or above.
Histologically confirmed breast cancer (invasive ductal cancer) by core biopsy, which is suitable for surgical resection.
Participants must have one non-metastatic, clinically palpable, invasive breast cancer measuring ≤2cm in its largest dimension, which can be visualised using diagnostic ultrasound.
All participants must have an adequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Adequate ECG, haematological, renal and hepatic function, as indicated, as would be required for imaging and surgery.
In the Investigator's opinion, is able and willing to comply with all trial requirements. Exclusion Criteria: Female participant who is pregnant.
Significant renal or hepatic impairment.
An inadequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Unable to visualize lesion or tumour boundaries clearly on ultrasound.
Subjects with tumours lying less than 5mm to overlying skin or less than 5mm to the underlying muscle on the diagnostic scan.
Any uncontrolled illness or any other medical problem that would preclude surgery.
The presence of any contraindication for magnetic resonance imaging, e.g. the presence of a heart pacemaker, a metallic foreign body (metal sliver) in the eye, or an aneurysm clip in the brain or severe claustrophobia.
Provide inclusion criteria for trial id: NCT05350059  
 Participant is willing and able to give informed consent for participation in the trial.
Female, aged 18 years or above.
Histologically confirmed breast cancer (invasive ductal cancer) by core biopsy, which is suitable for surgical resection.
Participants must have one non-metastatic, clinically palpable, invasive breast cancer measuring ≤2cm in its largest dimension, which can be visualised using diagnostic ultrasound.
All participants must have an adequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Adequate ECG, haematological, renal and hepatic function, as indicated, as would be required for imaging and surgery.
In the Investigator's opinion, is able and willing to comply with all trial requirements.
Provide exclusion criteria for trial id: NCT05350059  
 Female participant who is pregnant.
Significant renal or hepatic impairment.
An inadequate biopsy determination of oestrogen, progesterone, HER2 receptor status on pre-operative biopsy.
Unable to visualize lesion or tumour boundaries clearly on ultrasound.
Subjects with tumours lying less than 5mm to overlying skin or less than 5mm to the underlying muscle on the diagnostic scan.
Any uncontrolled illness or any other medical problem that would preclude surgery.
The presence of any contraindication for magnetic resonance imaging, e.g. the presence of a heart pacemaker, a metallic foreign body (metal sliver) in the eye, or an aneurysm clip in the brain or severe claustrophobia.
Provide description for trial id: NCT05350059  
 High Intensity Focused Ultrasound (HIFU) is a new method of treating solid tumours by thermally ablating them. It has been used in a number of different types of cancers but there is little information on its use in invasive breast cancer (IBC). The investigators aim to assess the efficacy and safety of HIFU in the treatment of IBC.

In this study, fifteen otherwise healthy women diagnosed with small, early stage IBC will be treated with HIFU prior to conventional surgical treatment. The effects of HIFU on the resected tumour will be analysed pathologically and correlated with radiological findings. Immune response and participant experience will also be evaluated
Trial Id: A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers Recruitment Status: Completed Trail description: The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer. Inclusion Criteria: Age > 18 years.
Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.
Patient desire to undergo breast surgery (lumpectomy or non-skin sparing mastectomy).
Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted.
The cancer enhances on prone breast MRI imaging
The cancer is visible on mammography. Exclusion Criteria: Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes.
Severe claustrophobia.
Contraindication to use of gadolinium-based intravenous contrast, including life- threatening allergy or compromised renal function (creatinine > 2.0).
History of median sternotomy.
Pregnancy. Patient attestation that they are not pregnant will be acceptable.
Patients receiving neoadjuvant chemotherapy.
Provide inclusion criteria for trial id: NCT03573661  
 Age > 18 years.
Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.
Patient desire to undergo breast surgery (lumpectomy or non-skin sparing mastectomy).
Ability to voluntarily provide informed consent to participate prior to any study-related assessments/procedures being conducted.
The cancer enhances on prone breast MRI imaging
The cancer is visible on mammography.
Provide exclusion criteria for trial id: NCT03573661  
 Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip, or metallic foreign body in or near eyes.
Severe claustrophobia.
Contraindication to use of gadolinium-based intravenous contrast, including life- threatening allergy or compromised renal function (creatinine > 2.0).
History of median sternotomy.
Pregnancy. Patient attestation that they are not pregnant will be acceptable.
Patients receiving neoadjuvant chemotherapy.
Provide description for trial id: NCT03573661  
 The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer.
Trial Id: Serum Retinoic Acid Induced Protein 14 (RAI14) and Metastasis Associated Cancer Colon -1 (MACC-1) in Breast Cancer Recruitment Status: Not yet recruiting Trail description: Measurement of serum levels of Retinoic acid induced 14 (RAI14) and Metastasis associated cancer colon -1 (MACC-1) as biomarkers for diagnosis of breast cancer.
Study their relationship to disease stages and clinicopathological features of BC.
Compare the diagnostic performance of serum RAI14 and serum MACC-1 with serum Carcinoembryonic antigen (CEA) and Cancer antigen 15-3 (CA15-3) for diagnosis of BC. Inclusion Criteria: None Exclusion Criteria: None
Provide description for trial id: NCT06097546  
 Measurement of serum levels of Retinoic acid induced 14 (RAI14) and Metastasis associated cancer colon -1 (MACC-1) as biomarkers for diagnosis of breast cancer.
Study their relationship to disease stages and clinicopathological features of BC.
Compare the diagnostic performance of serum RAI14 and serum MACC-1 with serum Carcinoembryonic antigen (CEA) and Cancer antigen 15-3 (CA15-3) for diagnosis of BC.
Trial Id: Whole Genome Sequencing in Breast Cancer Recruitment Status: Recruiting Trail description: This study aims to conduct whole genome sequencing in breast cancer patients to elucidate individual genetic characteristics and their correlation with breast cancer subtypes. The primary objective is to establish new treatment guidelines aligned with the paradigm shift in precision medicine. The study will include both prospective and retrospective cohorts totaling 1200 participants. Prospective participants must provide consent and be eligible for tissue collection, while retrospective participants must have histologically confirmed breast cancer and available tissue samples from Samsung Medical Center Biobank. The study period spans 3 years for subject enrollment and 5 years for follow-up observations, with an expected completion date of December 31, 2030. Inclusion Criteria: Patients who have consented to both the patient consent form and the consent for the use of human-derived materials.
Patients who are aged 19 years or older at the time of signing the consent form.
Patients capable of providing written consent to participate voluntarily in the study.
Patients eligible for tissue examination and surgical removal to facilitate sample collection.
Patients histologically confirmed with breast cancer or undergoing tissue examination for pathological confirmation due to imaging findings suggestive of breast cancer. Exclusion Criteria: Patients who do not understand or refuse to consent in writing.
Patients for whom obtaining sufficient samples is challenging.
Patients who refuse genetic testing.

[Retrospective study]

Inclusion Criteria:

Patients histologically confirmed with breast cancer.
Patients for whom breast cancer tissues collected between 2012 and 2023 are stored in the Samsung Seoul Hospital Biobank and available for distribution.

Exclusion Criteria:

- Patients for whom sufficient tissue for analysis is not adequately stored.
Provide inclusion criteria for trial id: NCT06334471  
 Patients who have consented to both the patient consent form and the consent for the use of human-derived materials.
Patients who are aged 19 years or older at the time of signing the consent form.
Patients capable of providing written consent to participate voluntarily in the study.
Patients eligible for tissue examination and surgical removal to facilitate sample collection.
Patients histologically confirmed with breast cancer or undergoing tissue examination for pathological confirmation due to imaging findings suggestive of breast cancer.
Provide exclusion criteria for trial id: NCT06334471  
 Patients who do not understand or refuse to consent in writing.
Patients for whom obtaining sufficient samples is challenging.
Patients who refuse genetic testing.

[Retrospective study]

Inclusion Criteria:

Patients histologically confirmed with breast cancer.
Patients for whom breast cancer tissues collected between 2012 and 2023 are stored in the Samsung Seoul Hospital Biobank and available for distribution.

Exclusion Criteria:

- Patients for whom sufficient tissue for analysis is not adequately stored.
Provide description for trial id: NCT06334471  
 This study aims to conduct whole genome sequencing in breast cancer patients to elucidate individual genetic characteristics and their correlation with breast cancer subtypes. The primary objective is to establish new treatment guidelines aligned with the paradigm shift in precision medicine. The study will include both prospective and retrospective cohorts totaling 1200 participants. Prospective participants must provide consent and be eligible for tissue collection, while retrospective participants must have histologically confirmed breast cancer and available tissue samples from Samsung Medical Center Biobank. The study period spans 3 years for subject enrollment and 5 years for follow-up observations, with an expected completion date of December 31, 2030.
Trial Id: Assessment of Periodontal Therapy and Biofilm Management in Breast Cancer Recruitment Status: Completed Trail description: Objective: To evaluate the impact of chemotherapy on periodontal conditions, hematology, and salivary flow in patients with breast cancer and gingivitis, after basic periodontal therapy (BPT).

Methods: They were divided into patients with breast cancer and gingivitis (BC/G =20); and patients without cancer with gingivitis (G=20). Clinical parameters [Plaque Index (PI), bleeding on probing (BOP), Probing Depth (PS), Clinical Attachment Level (CAL)], hematological parameters (complete blood count), and salivary flow were evaluated at baseline, 6, 12 and 24 weeks. Inclusion Criteria: None Exclusion Criteria: None
Provide description for trial id: NCT06212908  
 Objective: To evaluate the impact of chemotherapy on periodontal conditions, hematology, and salivary flow in patients with breast cancer and gingivitis, after basic periodontal therapy (BPT).

Methods: They were divided into patients with breast cancer and gingivitis (BC/G =20); and patients without cancer with gingivitis (G=20). Clinical parameters [Plaque Index (PI), bleeding on probing (BOP), Probing Depth (PS), Clinical Attachment Level (CAL)], hematological parameters (complete blood count), and salivary flow were evaluated at baseline, 6, 12 and 24 weeks.
Trial Id: Clinical Evaluation of OSNA Breast Cancer System to Extensive Frozen Section Histopathology Recruitment Status: Completed Trail description: The study will determine the sensitivity, specificity, negative predictive value and positive predictive value of the OSNA Breast Cancer System by comparing its performance to an extensive intraoperative frozen section protocol for Sentinel Lymph Nodes removed during standard Sentinel Lymph Node biopsy procedures from breast cancer subjects. Inclusion Criteria: Male or female;
18 years of age or older;
Diagnosed pre-surgically with T1 or T2 breast cancer without clinical evidence of axillary lymph node involvement and scheduled for surgery including sentinel lymph node dissection;
Subjects (or the subjects' legal representatives) who have read, understood to the best of their ability and signed the informed consent form. Exclusion Criteria: Subjects diagnosed pre-surgically with large or locally advanced (T3 & T4) breast cancer;
Pregnant subjects, confirmed by interview with either subject or treating physician;
Subjects diagnosed with inflammatory breast cancer;
Subjects diagnosed with ductal carcinoma in situ (DCIS) when breast conservation is to be done;
Subjects with clinically suspicious, palpable axillary lymph nodes;
Subjects previously treated for or previously diagnosed with another type of invasive cancer. Subjects with skin cancer (basal cell and squamous cell carcinoma) may be included, except for subjects diagnosed with melanoma; Subjects with non-invasive carcinoma of the Cervix may also be included in this study.
Subjects who have received pre-operative systemic therapy;
Subjects who are incapable of providing written informed consent;
Subjects who have been judged to be an inappropriate candidate by any medical care provider (e.g., surgeon, oncologist or pathologist).
Subjects participating in other clinical studies where the SLN evaluation will be negatively impacted by this study.
Provide exclusion criteria for trial id: NCT01368744  
 Subjects diagnosed pre-surgically with large or locally advanced (T3 & T4) breast cancer;
Pregnant subjects, confirmed by interview with either subject or treating physician;
Subjects diagnosed with inflammatory breast cancer;
Subjects diagnosed with ductal carcinoma in situ (DCIS) when breast conservation is to be done;
Subjects with clinically suspicious, palpable axillary lymph nodes;
Subjects previously treated for or previously diagnosed with another type of invasive cancer. Subjects with skin cancer (basal cell and squamous cell carcinoma) may be included, except for subjects diagnosed with melanoma; Subjects with non-invasive carcinoma of the Cervix may also be included in this study.
Subjects who have received pre-operative systemic therapy;
Subjects who are incapable of providing written informed consent;
Subjects who have been judged to be an inappropriate candidate by any medical care provider (e.g., surgeon, oncologist or pathologist).
Subjects participating in other clinical studies where the SLN evaluation will be negatively impacted by this study.
Trial Id: Breast Cancer With Over-expression of erbB2-BRAINSTORM Recruitment Status: Completed Trail description: This retrospective cohort study aims to improve our understanding of the current paradigm for treatment of brain metastases in erbB2+ breast cancer patients in the Asia Pacific region. We aim to identify approximately 300 erbB2+ breast cancer patients with brain metastases diagnosed between 2006-2008 in 6 countries. Medical records will be analyzed to determine the treatment pattern for brain metastases, including anti-erbB2 therapy. Additional objectives are to understand the impact of anti-erbB2 therapy on survival after brain metastases and to investigate the relationship between anti-erbB2 therapy for brain metastases and: 1) the time interval between diagnosis of erb2+ breast cancer and brain metastasis, and 2) the occurrence of brain metastasis as the first site of disease progression. Inclusion Criteria: Female patients diagnosed with erbB2+ breast cancer. ErbB2 positivity will be as determined by respective institutional standards, and will be based on medical history only.
Brain metastasis diagnosis made between January 2006 - December 2008. Exclusion Criteria: Women who have another primary cancer diagnosed between the time of breast cancer diagnosis and brain metastasis..
Patient has leptomeningeal metastases only without parenchymal brain involvement (since this pattern of the disease requires a different treatment approach.)